The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial.
- 2020-10
- Clinical Nutrition ESPEN 39
- K. Abhari
- Saeede Saadati
- Zahra Yari
- H. Hosseini
- M. Hedayati
- S. Abhari
- S. Alavian
- A. Hekmatdoost
- PubMed: 32859329
- DOI: 10.1016/j.clnesp.2020.06.020
Abstract
Background: The aim of this study was to evaluate the effects of supplementation with 109 spores of Bacillus coagulans (GBI-30) plus inulin in patients with non-alcoholic fatty liver disease (NAFLD).
Methods: In a randomized, double-blind, placebo-controlled clinical trial, fifty three patients with NAFLD were randomly assigned to receive either a synbiotic or a placebo capsule for 12 weeks. The primary outcome was reduction in steatosis score in Fibroscan exam.
Results: At the end of study, serum alanine aminotransferase and γ glutamine transaminase decreased significantly more in synbiotic group compared to placebo group (p = 0.001, and p = 0.004, respectively). Synbiotic supplementation significantly reduced serum tumor necrosis factor-α (p = 0.03) and nuclear factor-κB activity (p = 0.04). Moreover, hepatic steatosis reduced significantly more in synbiotic group compared to placebo group (p < 0.001).
Conclusion: Our results indicate that 12 weeks supplementation with B. coagulans plus inulin is beneficial for treatment of NAFLD and its related inflammation without any significant effects on related cardiovascular risk factors.
Clinical trials: This trial was registered at irct.ir with number of IRCT20100524004010N23.
Keywords: Bacillus coagulans; Clinical trial; Fatty liver; Probiotics.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bacillus coagulans | Reduced Gamma-Glutamyl Transferase Levels | Beneficial | Large |
| Bacillus coagulans | Reduced Hepatic Steatosis | Beneficial | Large |
| Bacillus coagulans | Reduced Nuclear Factor Kappa B Activation | Beneficial | Moderate |
| Bacillus coagulans | Reduced Serum Alanine Aminotransferase Levels | Beneficial | Large |
| Bacillus coagulans | Reduced Tumor Necrosis Factor Alpha | Beneficial | Moderate |
| Bacillus coagulans GBI-30, 6086 | Improved Liver Steatosis | Beneficial | Large |
| Bacillus coagulans GBI-30, 6086 | Reduced Nuclear Factor Kappa B Activation | Beneficial | Moderate |
| Bacillus coagulans GBI-30, 6086 | Reduced Serum Alanine Aminotransferase Levels | Beneficial | Large |
| Bacillus coagulans GBI-30, 6086 | Reduced Serum Gamma Glutamine Transaminase Levels | Beneficial | Large |
| Bacillus coagulans GBI-30, 6086 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Moderate |
| Bacillus coagulans MTCC 5856 | Reduced Hepatic Steatosis | Beneficial | Large |
| Bacillus coagulans MTCC 5856 | Reduced Nuclear Factor Kappa B Activation | Beneficial | Moderate |
| Bacillus coagulans MTCC 5856 | Reduced Serum Alanine Aminotransferase Levels | Beneficial | Large |
| Bacillus coagulans MTCC 5856 | Reduced Serum Gamma Glutamine Transaminase Levels | Beneficial | Large |
| Bacillus coagulans MTCC 5856 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Moderate |
| Bacillus coagulans ProDura | Reduced Inflammatory Markers | Beneficial | Moderate |
| Bacillus coagulans ProDura | Reduced Liver Enzyme Levels | Beneficial | Large |
| Bacillus coagulans SC208 | Reduced Gamma-Glutamyl Transferase Levels | Beneficial | Large |
| Bacillus coagulans SC208 | Reduced Hepatic Steatosis | Beneficial | Large |
| Bacillus coagulans SC208 | Reduced Nuclear Factor Kappa B Activation | Beneficial | Moderate |
| Bacillus coagulans SC208 | Reduced Serum Alanine Aminotransferase Levels | Beneficial | Large |
| Bacillus coagulans SC208 | Reduced Serum Tumor Necrosis Factor-α | Beneficial | Moderate |
| Bacillus coagulans SNZ-1969 | Reduced Hepatic Steatosis | Beneficial | Large |
| Bacillus coagulans SNZ-1969 | Reduced Nuclear Factor Kappa B Activation | Beneficial | Moderate |
| Bacillus coagulans SNZ-1969 | Reduced Serum Alanine Aminotransferase Levels | Beneficial | Large |
| Bacillus coagulans SNZ-1969 | Reduced Serum Gamma Glutamine Transaminase Levels | Beneficial | Large |
| Bacillus coagulans SNZ-1969 | Reduced Tumor Necrosis Factor Alpha | Beneficial | Moderate |
| Bacillus coagulans Unique IS-2 | Reduced Liver Fat | Beneficial | Large |
| Bacillus coagulans Unique IS-2 | Reduced Nuclear Factor Kappa B Activation | Beneficial | Moderate |
| Bacillus coagulans Unique IS-2 | Reduced Serum Alanine Aminotransferase Activity | Beneficial | Large |
| Bacillus coagulans Unique IS-2 | Reduced Serum Gamma Glutamine Transaminase Levels | Beneficial | Large |
| Bacillus coagulans Unique IS-2 | Reduced Serum Tumor Necrosis Factor-α | Beneficial | Moderate |